ODAIA Raises $15M Series C for Pharma Commercial Intelligence
Adding a second pharmaceutical brand can put an AI supplier back at the beginning: another team, another implementation, another negotiation over how the work should run. ODAIA is using its latest financing to pursue a more repeatable relationship with the enterprise customers it already serves, carrying commercial intelligence across brands and therapeutic areas.
The Toronto company announced a closed $15M Series C on November 17, 2026, led by Monograph Capital and anchored by strategic investor PHM, part of Publicis Groupe. The amount is denominated in U.S. dollars. Alongside the financing, a separate commercial agreement makes PHM ODAIA's exclusive U.S. agency partner, bringing a health-media business into the work of connecting pharmaceutical sales and marketing.
For pharma operators, the significance sits inside that connection. ODAIA sells software for deciding which healthcare professionals to engage and how to coordinate the contact. Its expansion plans make the company's ability to carry an agreed brand strategy through different teams and channels central to the customer relationship, with the agency now participating in execution as well as investment.
What ODAIA's Series C finances
Monograph Capital led the round after co-leading ODAIA's Series B. Returning investors include BDC Capital, Flint Capital, Innospark Ventures, Graphite Ventures, Threshold Ventures and Wittington Ventures. ODAIA says the proceeds will support growth inside existing enterprise pharma accounts and continued development of its commercial-intelligence platform; it has not announced a valuation or investor-by-investor allocations.
That use of proceeds gives the financing a particular commercial shape. Once a software supplier has earned a place with one brand, a wider customer portfolio offers more potential deployments. Each additional deployment also brings people with their own priorities and an existing way of working. Reusability becomes valuable when it reduces the work of carrying those differences into a shared system.
CEO and cofounder Philip Poulidis describes the burden of rebuilding for each new brand or therapeutic area as a scaling problem. ODAIA's response is to make brand strategy configurable within the platform. The purchasing question therefore extends to how much implementation work can travel from one brand to the next while each team retains the strategy appropriate to its therapy and market.
The historical financing record provides context without supplying a current financial verdict. ODAIA announced a $25M Series B in May 2023. Transaction counsel Osler also records its earlier US$13.8M Series A in February 2022. Those rounds document successive investments in the business; they leave current revenue, profitability and lifetime funding outside what this announcement establishes.
How ODAIA connects field calls and marketing
ODAIA's platform description divides commercial decisions into several connected jobs: scoring healthcare-professional opportunities, prioritizing calls, preparing context, sequencing campaigns and relating activity to prescription results. A recommendation has somewhere to go and a reason attached to it. For a commercial manager, that matters because a useful prediction still needs to become a decision somebody can understand and act upon.
The company describes Marketing Intelligence as a way to adjust channel, message and timing for individual healthcare professionals. Its stated measurement approach connects campaign engagement with prescription activity, feeding results into later decisions. These are vendor descriptions of commercial software capabilities. They should be read as such, with measurement definitions and implementation evidence remaining part of a customer's evaluation.
The workflow also reaches the tools field teams already use. ODAIA's CRM integration page names Veeva Vault CRM and Salesforce Life Sciences Cloud, placing prioritization and context within the healthcare professional's profile. That design choice puts adoption into an ordinary working moment: a rep preparing a call can encounter the guidance while looking at the customer record.
The organizational implication follows from that architecture. A brand strategy can lose coherence when a field team and a media team translate it into separate plans. Giving both a common set of priorities creates a basis for coordination, but the customer still needs to decide who owns the strategy, how changes are approved and how performance is interpreted across channels. Those are operating responsibilities that arrive with the software deployment.
Why PHM's agency role changes the relationship
PHM's November 17 announcement confirms both its strategic investment and its appointment as ODAIA's exclusive U.S. agency partner. The platform agreement is a distinct commercial arrangement, and its financial terms were not disclosed. ODAIA says it will continue working directly with pharmaceutical companies while the partnership connects digital-media activity and field sales around healthcare-professional priorities.
An agency relationship gives that connection a practical owner on the media side. PHM works on the campaigns through which a pharmaceutical brand reaches its audience, so the partnership places an execution business alongside the software making recommendations. From the buyer's perspective, discussions about data and models can now include the people responsible for putting the resulting media plan into motion.
ODAIA was founded in 2018 out of the University of Toronto and maintains offices in Toronto and Boston. Its current leadership page lists Philip Poulidis as CEO and cofounder and Zak Beharie as CTO, alongside academic cofounders Helen Kontozopoulos, Gael Bernard and Periklis Andritsos. The technical and commercial work now spans a wider relationship between the customer's brand organization, its field team and an agency partner.
For ODAIA, expansion within an enterprise account carries that whole relationship into the next brand discussion. The customer has another therapy to support, a field organization preparing calls and a media plan consuming budget. The opportunity is to let the work already done on commercial intelligence remain useful as those people bring a different brand's priorities to the table.
Healthcare AI funding, last 30 days
DevCuration's funding database tracked 24 Healthcare AI rounds totaling $6.5B in disclosed capital over the past 30 days. Recent deals we covered:
- Isomorphic Labs Raises $5B Series C for AI Drug DesignSeries C · $5B · Nov 18
- TestDynamics Secures $9M to Expand Imaging AI EvaluationSeries A · $9M · Nov 17
- Betterness Raises $1M to Expand Miami Wellness NetworksSeed Extension · $1M · Nov 16
- Knit Health Raises $35M Series A for Clinical AI DeploymentSeries A · $35M · Nov 16
- Remedy Robotics Raises $62M Series B for N1 Clinical TrialsSeries B · $62M · Nov 16
Frequently Asked Questions
Can pharma companies still work directly with ODAIA after the PHM agreement?
ODAIA says it will continue working directly with pharmaceutical companies. PHM is its exclusive U.S. agency partner under a separate commercial agreement; the announcement does not describe an end to direct sales.
How does ODAIA fit into an existing pharma CRM workflow?
ODAIA describes integrations with Veeva Vault CRM and Salesforce Life Sciences Cloud. The stated approach puts healthcare-professional priorities and explanatory context into the customer records field teams already use.
How do HCP prioritization and campaign coordination relate in ODAIA's platform?
Prioritization helps a team decide which healthcare professionals to engage. ODAIA describes connected tools for call planning, campaign sequencing and relating engagement to prescription activity, allowing field and marketing teams to work from shared priorities.
Why is deployment across brands important to ODAIA's expansion plan?
ODAIA says it will use the financing to grow within existing enterprise pharma accounts. Extending a shared commercial-intelligence foundation across brands and therapeutic areas addresses the repeated implementation work described by CEO Philip Poulidis.
Does prescription-related measurement establish a clinical benefit?
The described measurement concerns commercial engagement and prescription activity. The financing and product descriptions provide no clinical-trial evidence establishing improved patient outcomes, so commercial software claims should remain distinct from clinical efficacy.
Where the Money Moved
The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.
Subscribe to Where the Money Moved